ABOUT PROTECT
Company Introduction
Management Team
History
Protect Animal Health is founded in 2019 by a group of pet-loving scientist and biotech professionals
when they identified the vastly disproportional lag in healthcare development for animals compare to its
market growth. Protect leverages over 5 decades of robust human drug development experience to
expedite healthcare offerings for the un-met needs in the booming companion pet-care market.
Amongst all, cancer remains one of the biggest unmet-medical need for pets. Many pet patients
endure lengthy yet ineffective cancer treatments that makes both pet parents and pet’s limiting time
unnecessarily painful. Protect aims to tackle the issue by further developing the noble prize-winning
technology, PD-1/PD-L1 immune-checkpoint inhibitor, for pets. PD-1/PD-L1 are validated successes in
human cancer treatment, which continues to gain indication coverage until today. Protect is developing a
novel therapeutic vaccine to make immunotherapy accessible for pet use.
Protect Animal Health has garnered the support of prominent investors and its team consist of
seasoned professionals from institutions and companies such as Harvard, Columbia, Cambridge,
Boehringer Ingelheim and Merck to collectively bring forth advanced therapies for companion animals and
become a global leader in animal health.
Protector
In Hawaii, pets are known as the Protector. Pets protect not only their closest family member, but also the priceless memories made together. As human healthcare makes incredible leaps, in gene therapy, cell therapy and more, on the other hand, pets are faced with significant lack of proper treatment options, often having to take off-label medicine for human use. Protect searches globally for best healthcare solutions that are truly suitable for pets, particularly in highly prominent age-related disease. From PoC to animal trials, Protect seeks to bring advance healthcare options to market for our beloved pets.
Company Introduction
Protect Animal Health is a Taiwanese life science development company specializing in companion animal care. We are currently developing a novel therapeutic cancer vaccine for companion pet – PT-001. Immunotherapy has been widely proven in the human world, and we at Protect are dedicated to making such advance therapies accessible for our beloved pet children, driving the change for the outdated animal health landscape. Beyond the oncology drug, Protect utilizes our human drug development expertise to tackle unmet-needs in all high potential disease area in pets, also acting as an incubator valuable companion animal drug pipeline. We aim to become the lin pioneering a new standard for animal healthcare.
Operations Team
The operations team has been gradually expanding alongside the product development process. Currently, the team consists of a general manager and department heads overseeing various functions, including administration, research and development (R&D), product development, and finance. These leaders are responsible for managing and driving the tasks and initiatives within their respective departments.
Haolin Sung
Pearl Fong
Sean Liu
Dr. Peggy Liu
Tony Huang
Shumin Lin
Consultant Team
At Protect Animal Health, our current primary development technology is licensed from the research team led by Dr. Lan Geng-Li at Taipei Veterans General Hospital. This technology leverages the immune checkpoint mechanism, which has been proven effective in human studies, to develop new drugs. By applying the concept of immunotherapy, we aim to shift the current trend of biopharmaceutical drug development that primarily focuses on monoclonal antibody-based medicines.
Shelley Chou
Dr. Jiang
Dr. Keng-li Lan
Dr. Tong-Young Lee
Dr. Tom Lin
Peter Tsai
Dr. Chantal Cho
Haolin SungFounder, Chief Executive Officer
Over 20+ years of combined biotech/healthcare venture capital, M&A, IPO investment and operational management experience. Angel investor and board member of multiple biotech companies including Protect Animal Health
Pearl FongHead of Research and Development
Over 20+ years of combined human drug development and Business development experience. Managed and consulted on the development and CMC of over 30 drug prospect across all cycles and regulatory regions. Led the development of Mycenax Biotech’s anti-TNF drug - first biologics drug developed solely in Taiwan - from pre-clinical stage to commercialization. Out license multiple service and drug product to international markets.
Sean LiuChief of Project Officer
- Expertise in biochemistry, neuroscience, cell biology, and stem cell biology
- Oversees R&D projects, licensing initiatives, and alliances with partner companies
- Guides antibody, cell, and gene therapy development, including CMC, preclinical, and clinical activities
- Navigates regulatory landscape and manages project timelines and budgets
- Drives business development, collaborations, and strategic partnerships to expand company's portfolio and global presence
Dr. Peggy LiuScientific Director
Over 13+ years of biotech industry and research laboratory experience. Specialization in antibody drug and process optimization in drug development. Several scientific research received international licensing and patent with biopharma. Managed the R&D and also played key role in capital raising at AcadeMab Biomedical Inc. prior to joining Protect.
Tony HuangDirector of clinical Research
Over 15+ years of healthcare clinical research and project management industry experience. Directed multiple healthcare project with MicroBio group, Yonglin Healthcare foundation, a cancer-treatment dedicated foundation under the Foxconn group. Cross functional project experience entails biologics drug development, clinical research, project management, academia-industry collaboration.
Shumin LinSales and Marketing Director
Over 18+ years of healthcare industry’s sales, marketing and business development experience across Taiwan and China. Cross-functional leader of multiple veterinary FMCG and drug products in China region for major pharmaceutical companies. Deep veterinary project management, sales channel, and business development experience in China.
Shelley ChouFinance
- Chief Finance Officer, Healthbanks Biomedical
- Chief Operating Officer, TWI Pharmaceuticals, Inc.
- COO/CFO, Reber Genetics Co. Ltd.
- Corporate Finance Manager, GSK & Abbott Taiwan
- Senior Auditor, Deloitte Taiwan
Dr. Jiang Scientific and Veterinary Clinical Advisor
- Veterinarian at National Health Research Institutes
- Deputy Director at Jing Ying Animal Hospital
- Researcher at the Institute of Electro-Optical Engineering, National Taiwan Normal University
- Selected as one of the top 100 pet doctors by Business Weekly
- Ph.D. in Anatomy and Cell Biology from National Taiwan University College of Medicine
- Current Associated Researcher at National Taiwan University Hospital
- Current Director of the Taiwan Veterinary Internal Medicine Association
- Current Director of Zhonghe Duma Animal Hospital
Dr. Keng-li LanScientific and Technology
- National Yang-Ming University, M.D.
- University of Michigan, Pharmacology Ph.D.
- Associate Professor, National Yang-Ming University Medical School
- Director - Radiation Oncology, Taipei Veterans General Hospital
- Postdoctoral Scholar and Adjunct Lecturer, University of Texas MD Anderson Cancer Center
Dr. Tong-Young LeeScientific and Technology
- National Taiwan University, Department of Pathology, Ph.D.
- Research Fellow and Adjunct Lecturer, Harvard Medical School
- Research Fellow, Children’s Hospital Boston
- Chief Executive Officer – StemCyte Inc.
- Deputy Director – MicroBio Co. Ltd.
- Vice President – Diamond BioFund Inc.
- Founder & CEO – Celtec Inc.
Dr. Tom LinScientific and Technology
- University of Sydney, Nerology and Immunology Ph.D.
- University of Sydney, Cardiovascular Medicine and Surgery M.D.
- Columbia Business School, London Business School, HKU, EMBA
- Chairman, Lin BioScience Inc.
- Chairmain and CEO, Belite Bio
Peter TsaiDrug Development and Manufacturing
- University of Pennsylvania, Biotechnology M.S.
- The University of British Columbia, Biochemistry and Commerce, B.S.
- Chief Commercialization Officer, Libo Pharma Corp.
- Director, Global Vaccine Technical Operations, Merck
Dr. Chantal ChoInternational Regulatory Affairs
- University of Cambride, Pharmacology Ph.D
- The University of British Columbia, Experimental medicine MSc
- Simon Fraser University, Cell and Molecular Biology B.S
- Vice President, Tanvex Biologics Corp.